9 results about "Antidepressant" patented technology

The invention relates to a composition comprising a piperazine-benzazepine, a buffer and a surfactant, and uses of such compositions such as treating, preventing, and / or suppressing symptoms of schizophrenia, schizoaffective disorders, and / or Parkinson's disease. The compositions have improved parameters such as a lower variance in pH, improved stability during storage, and lower solubility of piperazine-benzazepines, resulting in piperazine-benzazepine particle formation with improved particle size and particle size distribution. The compositions are useful as therapeutic agent, for instance through parenteral administration to a subject.

The application discloses an IGFBP-2 derived polypeptide and application thereof in preparation of an antidepressant, and relates to the technical field of biological medicines. The amino acid sequence of the polypeptide is Pro-Lys-Lys-Leu-Arg-Pro, the N terminal of which is acetylated and the C terminal of which is amidated, and the amino acid sequence is shown as SEQ ID NO:1. The polypeptide has a small molecular weight, can easily penetrate the blood-brain barrier, and has good stability after terminal modification. Animal experiments prove that the polypeptide can significantly improve the depressive behavior of Shank3 gene knockout mice, including improving the spatial cognitive ability, enhancing the social interaction and curiosity, and relieving the anxiety behavior. Cell experiments prove that the polypeptide can significantly improve the viability of hippocampal neuron cells from Shank3 gene knockout mice, and up-regulate the expression level of synaptic plasticity related proteins GluA1 and SYN1. The polypeptide can be prepared by a chemical synthesis method, has low cost, and can be used for preparing a medicine for preventing or treating depression (especially depression related to Shank3 gene mutation).

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, an antidepressant, such as bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

This invention relates to the field of traditional Chinese medicine (TCM) technology, and particularly to a TCM composition for treating tinnitus. Its ingredients include: vinegar-processed turtle shell, stir-fried jujube seed, anemarrhena rhizome, phellodendron bark, rehmannia root, white peony root, poria cocos, fleeceflower root vine, scutellaria barbata, oldenlandia diffusa, stir-fried atractylodes macrocephala, prunella vulgaris, and cicada slough. The TCM composition of this invention exhibits significant multi-dimensional beneficial effects in treating tinnitus. Compared with Western medicine treatments, it avoids the side effects such as low blood pressure, dizziness, drowsiness, and dry mouth associated with vasodilators and antidepressants, and overcomes the drawbacks of physical therapy, which only temporarily relieves symptoms and cannot cure the condition. It has the advantages of holistic conditioning and fewer side effects, providing a safe, effective, and comprehensive treatment plan for tinnitus patients, and has high clinical application value and promotional significance.

This invention discloses a method for preparing anthocyanin-coated nanoparticles and their applications. First, anthocyanins and extracellular vesicles (EVs) are extracted from honeysuckle fruit to obtain anthocyanin powder. Then, PBS and squalene are added to the anthocyanin powder to obtain squalene@anthocyanin. Next, EVs are added to squalene@anthocyanin, co-incubated, and then centrifuged to obtain anthocyanin-coated nanoparticles. These nanoparticles have a particle size of 180-220 nm, a zeta potential of -45 to -55 mV, and an encapsulation efficiency ≥85%. They exhibit excellent stability and biocompatibility, possessing functions such as regulating gut microbiota, antidepressant, antioxidant, and anti-inflammatory effects. Furthermore, their good biocompatibility and low toxicity solve the problems of stability and bioavailability, achieving precise regulation of gut microbiota and providing a safe and efficient new approach for the treatment of depression.

This invention relates to the field of plant-derived extracellular vesicles, and discloses a method for preparing and applying Hypericum perforatum-derived exosome-like nanovesicles (HPDENs). This invention prepares HPDENs with natural vesicle structures through a specific process, utilizing the natural characteristics of plant-derived vesicles to encapsulate Hypericum perforatum (…). HP The active ingredient, combined with nasal drops, achieves targeted delivery to the brain. It exerts its antidepressant effect by regulating microglia polarization imbalance and reshaping the "neuroimmune-synaptic" axis. This solves the core problems of traditional antidepressants, such as slow onset of action, poor treatment response, and large side effects. It can also improve the core pathological features of depression (neuritis, synaptic plasticity damage) and improve depressive-like behaviors, providing a brand-new option for the clinical treatment of depression.

This invention belongs to the field of pharmaceutical formulation technology, specifically a transdermal sustained-release patch for antidepressants and its preparation method. The transdermal sustained-release patch for antidepressants provided by this invention comprises compounds as shown in Formula I. This invention provides a transdermal sustained-release patch for antidepressants that can maintain stable blood drug concentrations for a long period, reduce the frequency of administration, and improve treatment adherence and efficacy stability.

This application discloses succinimide derivatives in the field of organic chemistry, with the general structural formula shown in Formula V. During preparation, compound I reacts with compound II to yield compound III; compound III reacts with compound IV in the presence of a condensing agent to yield succinimide derivative V. The succinimide derivatives of this application can be used in the preparation of sedative, tranquilizing, nootropic, anticonvulsant, antiepileptic, antineuralgia, anti-anxiety, antidepressant, antidementia, and / or brain injury protective drugs.